Tata Capital Growth Fund to Invest ~USD 30 million (Rs 225 Crore) in Biocon Biologics for an Equity Stake of 0.85% Deal Values Biocon Biologics at USD 3.5 Billion.

  • Posted by: Biocon Biologics

Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr

  • Posted by: Biocon Biologics

Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins

  • Posted by: Biocon Biologics

Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19

  • Posted by: Biocon Biologics

Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients

  • Posted by: Biocon Biologics

Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award

  • Posted by: Biocon Biologics

Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®

  • Posted by: Biocon Biologics

Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients

  • Posted by: Biocon Biologics

Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity

  • Posted by: Biocon Biologics
Share
buy twitter followers - omegle - matadorbet güncel adres - onwin